A high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing

A high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing

C-Reactive Protein (CRP) is an acute phase reactant routinely used as a biomarker to assess either infection or inflammatory processes such as autoimmune diseases. CRP also has demonstrated utility as a predictive marker of future risk of cardiovascular disease. A new method of immunoassay for the detection of C-Reactive Protein has been developed using Resonant Acoustic Profilingtrade mark (RA...

Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.

C-reactive protein (CRP) is a prototypic marker of inflammation. Numerous prospective studies in healthy volunteers have confirmed that high-sensitivity CRP (hsCRP) predicts cardiovascular events (CVEs), and hsCRP seems additive to an elevated total cholesterol level and a total/high-density lipoprotein cholesterol ratio in men and women in predicting risk. In smokers and people with metabolic ...

High-Sensitivity C-Reactive Protein and Cancer

BACKGROUND High-sensitivity C-reactive protein (hs-CRP) is a commonly used inflammatory marker. The association between hs-CRP and cancer is less consistent than that between hs-CRP and cardiovascular diseases. This study explored the association between hs-CRP and cancer, using a large database of Korean health examination records. METHODS A total of 80,781 Koreans who visited the health pro...

High-sensitivity C-reactive protein methods examined.

Steatosis DeLIVERs high-sensitivity C-reactive protein.

Nonalcoholic fatty liver disease is characterized by excess accumulation of lipids within parenchymal cells of the liver (ie, hepatocellular steatosis) in the absence of excessive ethanol consumption. Fatty liver disease is widely considered to be the hepatic manifestation of metabolic syndrome and is estimated to occur in more than 25% of the Western population.1 Nonalcoholic fatty liver disea...